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Jennifer R Levy1,2,3,4, Kevin P Campbell1,2,3,4 and David J Glass5*Abstract
Mitsugumin 53 (MG53) is a relatively newly identified tripartite motif-containing (TRIM) family muscle-specific E3
ubiquitin ligase that is expressed in skeletal muscle and the heart. It has been postulated to facilitate repair by
targeting the site of an injury, and acting as a scaffold for assembly of a repair complex made up of dysferlin,
annexin V, caveolin-3, and polymerase I and transcript release factor (PTRF). A recent letter published in Nature by
Song et al. proposes an alternate function for MG53: as an E3 ligase that targets the insulin receptor and insulin
receptor substrate 1 (IRS1) for degradation, therefore regulating muscle insulin signaling. This work is exciting, as it
not only presents a novel role for MG53, but also suggests that muscle insulin signaling has a systemic influence on
insulin resistance and the metabolic syndrome.
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Metabolic syndrome is a disorder of increasing preva-
lence, especially in developed countries; it is associated
with an increase in the incidence of obesity and the
often-associated type 2 diabetes. It is defined as a cluster
of conditions comprising hypertension, high blood glu-
cose levels, abnormal cholesterol levels and central obes-
ity that, when they occur in combination, increase the
risk for cardiovascular disease and type 2 diabetes [1].
The majority of insulin-stimulated glucose disposal oc-
curs in skeletal muscle [2,3], and therefore it is likely
that insulin resistance in skeletal muscle is a precursor
to systemic metabolic dysfunction.
Mitsugumin 53 (MG53) is a cardiac and skeletal
muscle-specific protein, which was identified in a screen
using an immuno-proteomic monoclonal antibody li-
brary against proteins present in striated muscle [4].
MG53, also known as tripartite motif 72 (TRIM72), has
a molecular weight of 53 kD, and contains the prototyp-
ical tripartite motif, which includes a RING, B-box and
coiled-coil moiety. MG53 also has a SPRY domain at the
carboxy terminus [5]. Although MG53 contains a canon-
ical E3 ligase RING finger domain, its E3 ligase activity
was not confirmed until recently [6].* Correspondence: david.glass@novartis.com
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reproduction in any medium, provided the orCai et al. generated an MG53-null mouse, which de-
veloped slowly progressive muscle pathology: mice aged
10 to 11 months had increased numbers of central nu-
clei and decreased muscle fiber diameter. The skeletal
muscle from MG53-null mice had increased Evans blue
dye uptake after downhill running, suggesting that these
mice have increased susceptibility to membrane injury.
Further experiments by this group of researchers impli-
cated MG53 as a central player in the repair of mem-
brane damage; it acts by binding to phosphatidylserine
at the damage site and acts as a scaffold to recruit a
complex of repair proteins that includes dysferlin,
annexin V, caveolin-3 and polymerase I and transcript
release factor (PTRF) [5,7]. Although MG53 has been
found to be upregulated in muscular dystrophy patients
[8], no pathogenic MG53 mutations have been identified.Discussion
Recently, Song et al. published a series of experiments
that identify a novel role for MG53 as a mediator of in-
sulin signaling [6]. The authors observed that animal
models for metabolic syndrome (high-fat diet (HFD)-in-
duced obese mice, db/db diabetic mice, spontaneously
hypertensive rats and non-human primate models of
metabolic syndrome), as well as obese humans, have in-
creased expression of MG53 compared to control ani-
mals and non-obese humans.d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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metabolic syndrome, the authors fed MG53-null mice
and wild-type littermates a HFD. MG53-null mice were
protected from increases in body weight, blood pressure,
and serum cholesterol and triglyceride levels. Further,
the loss of MG53 blocked HFD-induced systemic insulin
resistance. Conversely, a transgenic mouse model that
overexpresses MG53 had the hallmarks of metabolic
syndrome (increased body weight, blood pressure and
serum cholesterol levels) and insulin resistance in the
absence of a HFD [6].
The authors delved into the mechanism for the regula-
tion of insulin signaling by MG53. Insulin stimulation
leads to autophosphorylation of the insulin receptor.
This leads to phosphorylation of insulin receptor sub-
strate 1 (IRS1) and insulin receptor substrate 2 (IRS2),
which in turn activates the phosphatidylinositol-3-OH
kinase (PI(3)K)-Akt-GSK3-beta signaling pathway. This
pathway mediates glucose homeostasis in skeletal muscle
[9]. Previously, Ko and colleagues [10] showed that
MG53 overexpression prevented IRS1 phosphorylation
and myogenesis in C2C12 myoblasts. The current study
found that MG53-null tissues had increased insulin sig-
naling, whereas MG53 overexpression suppresses insulin
signaling. Changes in insulin signaling accompanied
marked changes in insulin receptor and IRS1 protein
levels, but not mRNA levels. Surprisingly, skeletal
muscle insulin resistance in MG53 transgenic mice pre-
ceded whole-body insulin disorders (obesity and multi-
organ insulin resistance). Specific inhibition of the E3
ubiquitin ligase activity of MG53 by deletion of the
RING finger domain or by mutation of a cysteine to an
alanine at position 14 suppresses the effects of MG53 on
insulin receptor activity and ubiquitination. This sup-
ports a model for MG53 targeting insulin receptor deg-
radation via its E3 ubiquitination ligase activity; the
downstream ubiquitination of IRS1 seems dependent on
the initial insulin receptor degradation, since IRS1 was
not degraded upon IGF1 stimulation. Therefore it seems
that IRS1 may be a ‘bystander’ – ubiquitinated due to its
proximity to the insulin receptor/MG53 complex. The
negative regulation of insulin signaling in skeletal muscle
by MG53 triggers systemic changes in insulin function
and metabolism.
Conclusions
The compelling results presented in Song et al. suggest
a novel role for MG53. It is interesting to speculate on
how to reconcile its new identity as an E3 ubiquitin lig-
ase that targets insulin signaling pathways with its ca-
nonical role as a membrane repair protein. It is possible
that MG53 performs two disparate functions in skeletal
muscle – it could exist in two functional pools, perhaps
mediated by localization or post-translational modification.Alternatively, its roles may be synergistic. For instance, the
direct interaction of MG53 with the insulin receptor and
IRS1 [6] could direct MG53 to the cell surface, where it
will be readily available when sarcolemmal disruptions re-
quire its activity as a repair protein. In support of a correl-
ation between muscle membrane repair defects and
insulin resistance, myocytes from db/db diabetic mice
show increased dye uptake after laser damage, indicating
reduced efficiency of membrane repair. Downhill running
of db/db mice showed increased permeability of myocytes
from these mice to Evans blue dye compared to wild-type
mice [11]. Interestingly, deletion of the MG53-interacting
proteins PTRF or caveolin-3 cause glucose intolerance
and insulin resistance, as opposed to the protective effect
seen in MG53-null mice, suggesting that members of the
membrane repair complex have opposing roles in insulin
signaling [12,13].
Alternatively, the E3 ubiquitin ligase activity of MG53
may act on targets in addition to insulin receptors and
IRS1. The ubiquitin-mediated degradation of these po-
tential targets may facilitate membrane repair using a
mechanism that is not yet known. Interestingly, MG53
has recently been shown to interact with and attenuate
the activity of sarcoplasmic reticulum calcium-ATPase
1a (SERCA1a) [14] – it is possible that SERCA is an
additional target for the E3 ubiquitin-ligase activity of
MG53.
One of the more surprising findings by Song et al. is
that the insulin resistance observed in MG53 transgenic
mice preceded changes in body weight and composition,
suggesting that MG53 action in muscle alters the whole-
body energy balance. The effects of insulin signaling spe-
cifically in muscle have been studied previously in mice
with muscle-specific inactivation of the insulin receptor
gene (muscle-specific insulin receptor knockout (MIRKO)
mice) [15]. These mice show relatively minor changes in
glucose homeostasis [15], possibly because the redistribu-
tion of substrates to adipose tissue causes increased adi-
posity in these mice [16]. It is possible that Song et al.
observed a similar phenomenon in the MG53-transgenic
mice: overexpression of MG53 targets insulin receptors
for degradation, which could lead to redistribution of sub-
strates to adipose tissue and, subsequently, metabolic
syndrome.
Song et al. found elevated levels of the MG53 protein
in obese humans and in several animal models for insu-
lin resistance and metabolic disorders, including HFD-
induced obese mice. It is unclear what mechanism is
responsible for increased MG53 expression in situations
of nutritional overload. Interestingly, a recent study by
Ko and colleagues [17] confirms that MG53 is a ubiqui-
tin E3 ligase that induces IRS-1 ubiquitination, and that
MG53-null mice fed a high-fat and high-sucrose diet are
protected from insulin resistance. However, this group
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betes patients had normal levels of the MG53 protein.
Ko and colleagues also challenged the finding by Song
et al. that insulin receptor is a substrate of MG53 be-
cause insulin receptor protein levels and phosphoryl-
ation are unchanged when MG53 is overexpressed in
myoblasts or genetically disrupted in knockout mice.
These inconsistencies highlight a need for further study
of the role of MG53 in insulin signaling and metabolism.
Recently, Weisleder et al. explored recombinant
MG53 protein therapy in mouse models of muscular
dystrophy [18]. They found that exogenous recombinant
human MG53 reduced muscle membrane damage and
decreased muscle pathology in mdx mice. While these
results suggest MG53 protein administration could be
therapeutic for Duchenne and potentially other muscular
dystrophies, the results from Song et al. should serve to
caution researchers to examine insulin resistance and
other hallmarks of metabolic disorders in treatment
groups. It is even possible that changes in insulin signal-
ing are somehow driving the improved pathology ob-
served in MG53-treated mdx mice.
In addition to discovering a new cellular role for
MG53, Song et al. identified MG53-mediated suppres-
sion of insulin signaling as having the capacity to under-
lie systemic insulin resistance and metabolic syndrome.
Muscle researchers should be excited to consider MG53
and skeletal muscle insulin signaling as central players in
the development of metabolic syndrome.
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